Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone

Carrie P. Earthman, Phyllis M. Reid, Ingeborg T. Harper, Eric Ravussin, Wanda H Howell

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: The aim of this study was to measure changes in body cell mass (BCM) and quality of life in HIV-infected individuals undergoing oxandrolone therapy. Previous studies on oxandrolone have neither quantified changes in BCM using criterion methods nor quality of life using an HIV-specific instrument. Methods: Twenty-five HIV-infected patients (15 with an AIDS diagnosis) on standard antiretroviral and nutrition management were studied before and an average of 18.6 weeks after the initiation of oxandrolone therapy, as prescribed by their primary care physician for the treatment of weight loss. BCM was estimated from intracellular water measured by multiple dilution. Lean soft-tissue mass (LTM) was measured by dual-energy X-ray absorptiometry. Quality of life was evaluated by the Functional Assessment of HIV Infection (FAHI) questionnaire. Results: Significant gains in body weight (2.6 ± 3.0 kg; p < .0001), BCM (3.6 ± 3.0 kg; p < .0001), and LTM (3.0 ± 2.9 kg; p < .0001) occurred over an average course of 18.6 weeks of treatment. Overall quality of life improved (p = .056) and appetite improved (p = .032), both of which were positively associated with weight gain (p = .040 and p = .022, respectively). Conclusions: This is the first study involving oxandrolone therapy in HIV infection to document changes in quality of life and BCM, the metabolically active component of lean body mass that reflects nutritional status better than other more global body composition parameters. Nutritional status and quality of life can improve in HIV-infected individuals receiving a combined therapeutic approach that includes oxandrolone.

Original languageEnglish (US)
Pages (from-to)357-365
Number of pages9
JournalJournal of Parenteral and Enteral Nutrition
Volume26
Issue number6
StatePublished - Nov 2002

Fingerprint

Oxandrolone
repletion
quality of life
Quality of Life
HIV
therapeutics
cells
Nutritional Status
HIV infections
HIV Infections
Therapeutics
nutritional status
Nutritive Value
Photon Absorptiometry
Primary Care Physicians
Appetite
dual-energy X-ray absorptiometry
Body Composition
lean body mass
Weight Gain

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. / Earthman, Carrie P.; Reid, Phyllis M.; Harper, Ingeborg T.; Ravussin, Eric; Howell, Wanda H.

In: Journal of Parenteral and Enteral Nutrition, Vol. 26, No. 6, 11.2002, p. 357-365.

Research output: Contribution to journalArticle

Earthman, Carrie P. ; Reid, Phyllis M. ; Harper, Ingeborg T. ; Ravussin, Eric ; Howell, Wanda H. / Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. In: Journal of Parenteral and Enteral Nutrition. 2002 ; Vol. 26, No. 6. pp. 357-365.
@article{6afce4b3609c45ffaae3b1692c7a49b8,
title = "Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone",
abstract = "Background: The aim of this study was to measure changes in body cell mass (BCM) and quality of life in HIV-infected individuals undergoing oxandrolone therapy. Previous studies on oxandrolone have neither quantified changes in BCM using criterion methods nor quality of life using an HIV-specific instrument. Methods: Twenty-five HIV-infected patients (15 with an AIDS diagnosis) on standard antiretroviral and nutrition management were studied before and an average of 18.6 weeks after the initiation of oxandrolone therapy, as prescribed by their primary care physician for the treatment of weight loss. BCM was estimated from intracellular water measured by multiple dilution. Lean soft-tissue mass (LTM) was measured by dual-energy X-ray absorptiometry. Quality of life was evaluated by the Functional Assessment of HIV Infection (FAHI) questionnaire. Results: Significant gains in body weight (2.6 ± 3.0 kg; p < .0001), BCM (3.6 ± 3.0 kg; p < .0001), and LTM (3.0 ± 2.9 kg; p < .0001) occurred over an average course of 18.6 weeks of treatment. Overall quality of life improved (p = .056) and appetite improved (p = .032), both of which were positively associated with weight gain (p = .040 and p = .022, respectively). Conclusions: This is the first study involving oxandrolone therapy in HIV infection to document changes in quality of life and BCM, the metabolically active component of lean body mass that reflects nutritional status better than other more global body composition parameters. Nutritional status and quality of life can improve in HIV-infected individuals receiving a combined therapeutic approach that includes oxandrolone.",
author = "Earthman, {Carrie P.} and Reid, {Phyllis M.} and Harper, {Ingeborg T.} and Eric Ravussin and Howell, {Wanda H}",
year = "2002",
month = "11",
language = "English (US)",
volume = "26",
pages = "357--365",
journal = "Journal of Parenteral and Enteral Nutrition",
issn = "0148-6071",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone

AU - Earthman, Carrie P.

AU - Reid, Phyllis M.

AU - Harper, Ingeborg T.

AU - Ravussin, Eric

AU - Howell, Wanda H

PY - 2002/11

Y1 - 2002/11

N2 - Background: The aim of this study was to measure changes in body cell mass (BCM) and quality of life in HIV-infected individuals undergoing oxandrolone therapy. Previous studies on oxandrolone have neither quantified changes in BCM using criterion methods nor quality of life using an HIV-specific instrument. Methods: Twenty-five HIV-infected patients (15 with an AIDS diagnosis) on standard antiretroviral and nutrition management were studied before and an average of 18.6 weeks after the initiation of oxandrolone therapy, as prescribed by their primary care physician for the treatment of weight loss. BCM was estimated from intracellular water measured by multiple dilution. Lean soft-tissue mass (LTM) was measured by dual-energy X-ray absorptiometry. Quality of life was evaluated by the Functional Assessment of HIV Infection (FAHI) questionnaire. Results: Significant gains in body weight (2.6 ± 3.0 kg; p < .0001), BCM (3.6 ± 3.0 kg; p < .0001), and LTM (3.0 ± 2.9 kg; p < .0001) occurred over an average course of 18.6 weeks of treatment. Overall quality of life improved (p = .056) and appetite improved (p = .032), both of which were positively associated with weight gain (p = .040 and p = .022, respectively). Conclusions: This is the first study involving oxandrolone therapy in HIV infection to document changes in quality of life and BCM, the metabolically active component of lean body mass that reflects nutritional status better than other more global body composition parameters. Nutritional status and quality of life can improve in HIV-infected individuals receiving a combined therapeutic approach that includes oxandrolone.

AB - Background: The aim of this study was to measure changes in body cell mass (BCM) and quality of life in HIV-infected individuals undergoing oxandrolone therapy. Previous studies on oxandrolone have neither quantified changes in BCM using criterion methods nor quality of life using an HIV-specific instrument. Methods: Twenty-five HIV-infected patients (15 with an AIDS diagnosis) on standard antiretroviral and nutrition management were studied before and an average of 18.6 weeks after the initiation of oxandrolone therapy, as prescribed by their primary care physician for the treatment of weight loss. BCM was estimated from intracellular water measured by multiple dilution. Lean soft-tissue mass (LTM) was measured by dual-energy X-ray absorptiometry. Quality of life was evaluated by the Functional Assessment of HIV Infection (FAHI) questionnaire. Results: Significant gains in body weight (2.6 ± 3.0 kg; p < .0001), BCM (3.6 ± 3.0 kg; p < .0001), and LTM (3.0 ± 2.9 kg; p < .0001) occurred over an average course of 18.6 weeks of treatment. Overall quality of life improved (p = .056) and appetite improved (p = .032), both of which were positively associated with weight gain (p = .040 and p = .022, respectively). Conclusions: This is the first study involving oxandrolone therapy in HIV infection to document changes in quality of life and BCM, the metabolically active component of lean body mass that reflects nutritional status better than other more global body composition parameters. Nutritional status and quality of life can improve in HIV-infected individuals receiving a combined therapeutic approach that includes oxandrolone.

UR - http://www.scopus.com/inward/record.url?scp=0036838939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036838939&partnerID=8YFLogxK

M3 - Article

C2 - 12405647

AN - SCOPUS:0036838939

VL - 26

SP - 357

EP - 365

JO - Journal of Parenteral and Enteral Nutrition

JF - Journal of Parenteral and Enteral Nutrition

SN - 0148-6071

IS - 6

ER -